3 articles
Novo Nordisk licensed its Parkinson's cell therapy program to Cellular Intelligence and shut its internal cell therapy unit. The company's shares gained 24.9% over 30 days as investors backed its GLP-1 refocus. The move reflects a broader pharma trend of outsourcing early-stage biology to AI-native partners while concentrating resources on validated commercial assets.
Novo Nordisk's decision to shutter its internal cell therapy unit and hand its Parkinson's program to AI-enabled Cellular Intelligence triggered a 24.9% stock surge, signalling market approval for asset-light, AI-accelerated models. NVIDIA's BioNeMo platform is emerging as the connective infrastructure linking European pharma incumbents to a new generation of AI-native drug discovery companies. A concurrent wave of specialised biological foundation models indicates the platform layer is maturing
Swiss specialty pharmaceutical company Santhera Pharmaceuticals faces significant pipeline concentration risk, with its entire commercial future effectively staked on a single asset — vamorolone — for Duchenne Muscular Dystrophy. As the company has already licensed out its Japan and Asia-Pacific rights to Nxera, any setback to vamorolone's European trajectory could leave thousands of DMD patients without a key treatment alternative and Santhera with little commercial fallback.
